Beat AML Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2016
NCT03013998
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Beat AML, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 7